CoChat

Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing

Open access

The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.

Abstract

Motivation: Transcriptome-based computational drug repurposing has attracted considerable interest by bringing about faster and more cost-effective drug discovery. Nevertheless, key limitations of the current drug connectivity-mapping paradigm have been long overlooked, including the lack of effective means to determine optimal query gene signatures. Results: The novel approach Dr Insight implements a frame-breaking statistical model for the ‘hand-shake’ between disease and drug data. The genome-wide screening of concordantly expressed genes (CEGs) eliminates the need for subjective selection of query signatures, added to eliciting better proxy for potential disease-specific drug targets. Extensive comparisons on simulated and real cancer datasets have validated the superior performance of Dr Insight over several popular drug-repurposing methods to detect known cancer drugs and drug–target interactions. A proof-of-concept trial using the TCGA breast cancer dataset demonstrates the application of Dr Insight for a comprehensive analysis, from redirection of drug therapies, to a systematic construction of disease-specific drug-target networks. Availability and implementation: Dr Insight R package is available at https://cran.r-project.org/web/packages/DrInsight/index.html. Supplementary information: Supplementary data are available at Bioinformatics online.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/bioinformatics/btz006

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Workflow of Dr Insight. (A) The gene rank list from the differential analysis (e.g. tumor versus normal) on the disease dataset is used as input. The reference database contains the gene rank lists (drug instances) from CMap. (B) Type 1 and type 2 CEGs are identified using order statistics. The bar plot shows the log P-values of type 1 (blue) and type 2 (red) CEGs. (C) An outlier-sum score (OS) is calculated for each drug instance and are used to perform K-S test, where the OS scores of the instances from one drug treatment set (red x’s) are compared against the rest of the drug instances. (D) Between-drug and within-drug tests are performed to identify disease-specific drug-pathway regulations. The node is colored by the average z-scores of CEGs within a pathway. (E) The output of Dr Insight: a drug-pathway connection network. The size of the pathways (orange circles) are proportional to their node degrees
Fig. 1. Workflow of Dr Insight. (A) The gene rank list from the differential analysis (e.g. tumor versus normal) on the disease dataset is used as input. The reference database contains the gene rank lists (drug instances) from CMap. (B) Type 1 and type 2 CEGs are identified using order statistics. The bar plot shows the log P-values of type 1 (blue) and type 2 (red) CEGs. (C) An outlier-sum score (OS) is calculated for each drug instance and are used to perform K-S test, where the OS scores of the instances from one drug treatment set (red x’s) are compared against the rest of the drug instances. (D) Between-drug and within-drug tests are performed to identify disease-specific drug-pathway regulations. The node is colored by the average z-scores of CEGs within a pathway. (E) The output of Dr Insight: a drug-pathway connection network. The size of the pathways (orange circles) are proportional to their node degreesCC BY-NC · PubMed Central
Fig. 2. Overlap of detected drugs (P-value ≤ 0.05) using different signature sizes on the TCGA breast cancer dataset. Five signature sizes at probe level are selected: 50, 100, 300, 600 and 1000. (A) CMap. (B) sscMap. (C) NFFinder
Fig. 2. Overlap of detected drugs (P-value ≤ 0.05) using different signature sizes on the TCGA breast cancer dataset. Five signature sizes at probe level are selected: 50, 100, 300, 600 and 1000. (A) CMap. (B) sscMap. (C) NFFinderCC BY-NC · PubMed Central
Fig. 3. Comparing Dr Insight with existing methods on cancer datasets. The bar plots give the log-transformed enrichment P-values from the five methods. Multiple enrichment P-values are reported for CMap, sscMap and NFFinder, which correspond to query signatures of different sizes. The horizontal lines indicate the 0.05 statistical significance level. (A) TCGA breast cancer dataset. (B) TCGA prostate cancer dataset. (C) GEO prostate cancer dataset
Fig. 3. Comparing Dr Insight with existing methods on cancer datasets. The bar plots give the log-transformed enrichment P-values from the five methods. Multiple enrichment P-values are reported for CMap, sscMap and NFFinder, which correspond to query signatures of different sizes. The horizontal lines indicate the 0.05 statistical significance level. (A) TCGA breast cancer dataset. (B) TCGA prostate cancer dataset. (C) GEO prostate cancer datasetCC BY-NC · PubMed Central
Fig. 4. Percentages of the identified drugs with statistically significant enrichment in known drug targets from drug-target databases. (A) Results from STITCH database. (B) Results from the CTD database
Fig. 4. Percentages of the identified drugs with statistically significant enrichment in known drug targets from drug-target databases. (A) Results from STITCH database. (B) Results from the CTD databaseCC BY-NC · PubMed Central
Fig. 5. Reconstructed breast cancer drug–pathway–gene connections for TCGA breast cancer data. (A) Reconstructed drug–pathway interaction network. (B) Representative target pathways of TSA and the potential target genes. Blue hexagons are the pathway genes that are identified as TSA CEGs and being documented as TSA targets in the CTD database; blue circles are the novel unregistered TSA CEGs. The networks are visualized using Cytoscape (Shannon et al., 2003)
Fig. 5. Reconstructed breast cancer drug–pathway–gene connections for TCGA breast cancer data. (A) Reconstructed drug–pathway interaction network. (B) Representative target pathways of TSA and the potential target genes. Blue hexagons are the pathway genes that are identified as TSA CEGs and being documented as TSA targets in the CTD database; blue circles are the novel unregistered TSA CEGs. The networks are visualized using Cytoscape (Shannon et al., 2003)CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

See all 50

Metadata

Authors
Chan, J., Wang, X., Turner, J. A., Baldwin, N. E., & Gu, J.
Affiliations
  • Baylor University (US)
  • Baylor Scott & White Research Institute (US)
  • Stephen F. Austin State University (US)
Corresponding author
Gu, Jinghua
Venue
Bioinformatics
Published
2019-01-08
Volume
35
Issue
16
Pages
2818-2826
ISSN
  • 1367-4803 (ISSN-L)
  • 1367-4811
OpenAlex
W2910665348
Cited by
50
References
57
Citations by year
2026: 3 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 12 · 2021: 7 · 2020: 13 · 2019: 3
FWCI
5.95
Type
journal article
Language
en
Open access
Locations
  • Bioinformatics (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Index of Texas Archaeology Open Access Grey Literature from the Lone Star State (submittedVersion)
Funders
National Institute of Allergy and Infectious Diseases (U19AI082715)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
Keywords
computational drug repurposing, drug-target interactions, cancer drug targets, breast cancer
MeSH terms
Software, Models, Statistical, Drug Discovery, Drug Repositioning, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing. https://app.cochat.ai/papers/10.1093/bioinformatics/btz006
The paper
Chan, J., Wang, X., Turner, J. A., Baldwin, N. E., & Gu, J. (2019). Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing. Bioinformatics. https://doi.org/10.1093/bioinformatics/btz006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.